Skip to search formSkip to main contentSkip to account menu

AC 7700

Known as: AVE8062, Combretastatin A4 Analogue AVE8062, AC7700 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Serine
analogs & derivatives

Narrower (1)

ombrabulin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
New vascular disrupting agents in upper gastrointestinal malignancies.
Antivascular approaches aim to cause rapid and catastrophic shutdown in the vascular function of the tumour, leading to extensive… 
Review
2013
Review
2013
Combretastatin A-4 and its Analogs in Cancer Therapy
Combretastatin A-4 (CA-4) is an anti-mitotic agent that is gaining rapid recognition among cancer biologists and clinicians as… 
2008
2008
A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with…
AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA LB-302 Abstract LB-302 is scheduld in a Late-Breaking Abstract session… 
Review
2007
Review
2007
Small molecule vascular disrupting agents: potential new drugs for cancer treatment.
Vascular disrupting agents (VDAs) are a new class of potential anticancer drugs that selectively destroy tumor vasculature and… 
2006
2006
In vivo synergy combining oxaliplatin with AVE8062, a vascular-disrupting agent.
13074 Background: AVE8062 is a synthetic, water-soluble compound, analog of Combretastatin A4, currently in Phase I clinical… 
Review
2005
Review
2005
Antineoplastic Strategy: Irreversible Tumor Blood Flow Stasis Induced by the Combretastatin A-4 Derivative AVE8062 (AC7700)
Despite extensive research efforts, effective therapies for refractive cancers have not yet been established, and development of… 
2002
2002
Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer
AbstractBackground. Unlike the many chemotherapeutic agents that do not effectively stop blood flow or induce necrosis in… 
2001
2001
Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect.
BACKGROUND Using several transplanted tumors in rats and mice, we have recently shown that the acute extensive necrosis of tumor… 
Highly Cited
1999
Highly Cited
1999
Evaluation of Antivascular and Antimitotic Effects of Tubulin Binding Agents in Solid Tumor Therapy
Tubulin binding agents (TBAs) reduce tumor perfusion and inhibit mitosis of tumor cells in solid tumors, but it is not clear… 
1999
1999
Synthesis and antitumor activities of amino acid prodrugs of amino-combretastatins.
The synthesis and antitumor activity of water-soluble amino acid prodrugs of amino-combretastatins were reported. Among the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)